Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia:: A 12-week double-blind, placebo-controlled pilot study

被引：54

作者：

Baptista, Trino ^{[1
]}

Uzcategui, Euderruh ^{[2
]}

Rangel, Nairy ^{[3
]}

El Fakih, Yamily ^{[2
]}

Galeazzi, Tatiana ^{[4
]}

Beaulieu, Serge ^{[5
]}

de Baptista, Enma Araujo ^{[6
]}

机构：

[1] Univ Los Andes, Sch Med, Dept Physiol, Merida 5101A, Venezuela

[2] Univ Los Andes, Sch Med, Dept Psychiat, Merida 5101A, Venezuela

[3] Psychiat Inst Dr Raul Castillo, San Cristobal, Tachira State, Venezuela

[4] Univ Los Andes, Sch Med, LABIEMET, San Cristobal, Venezuela

[5] McGill Univ, Douglas Hosp, Res Ctr, Montreal, PQ, Canada

[6] Univ Los Andes, Sch Med, Sch Pharm, Dept Microbiol, Merida 5101A, Venezuela

来源：

PSYCHIATRY RESEARCH | 2008年 / 159卷 / 1-2期

关键词：

atypical antipsychotics; metabolic dysfunction; pharmacological treatment;

D O I：

10.1016/j.psychres.2008.01.011

中图分类号：

R749 [精神病学];

学科分类号：

100205 [精神病与精神卫生学];

摘要：

Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients. Weight loss was similar in both groups: -2.8 +/- 3.2 kg vs. -1.4 +/- 2.6 kg. Except for preventing a triglyceride increase, the drug combination lacked efficacy for metabolic control in this clinical population. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：250 / 253

页数：4

共 8 条

[1]

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration:: A multicentric, double-blind, placebo-controlled trial [J].

Baptista, Trino ;

Rangel, Nairy ;

Fernandez, Virginia ;

Carrizo, Edgardo ;

El Fakih, Yarnily ;

Uzcategui, Euderruh ;

Galeazzi, Tatiana ;

Gutierrez, Maria A. ;

Servigna, Mercedes ;

Davila, Adriana ;

Uzcategui, Marycelvia ;

Serrano, Ana ;

Connell, Lisette ;

Beaulieu, Serge ;

de Baptista, Enma Araujo .

SCHIZOPHRENIA RESEARCH, 2007, 93 (1-3) :99-108

[2]

Weight loss in overweight patients maintained on atypical antipsychotic agents [J].

Centorrino, F. ;

Wurtman, J. J. ;

Duca, K. A. ;

Fellman, V. H. ;

Fogarty, K. V. ;

Berry, J. M. ;

Guay, D. M. ;

Romeling, M. ;

Kidwell, J. ;

Cincotta, S. L. ;

Baldessarini, R. J. .

INTERNATIONAL JOURNAL OF OBESITY, 2006, 30 (06) :1011-1016

[3]

Interventions to reduce weight gain in schizophrenia [J].

Faulkner, G. ;

Cohn, T. ;

Remington, G. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (01)

[4]

Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome [J].

Glueck, Charles J. ;

Aregawi, Dawit ;

Agloria, Mahlia ;

Winiarska, Magdalena ;

Sieve, Luann ;

Wang, Ping .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (12) :1582-1589

[5]

Hägg S, 2002, CNS DRUGS, V16, P765

[6]

Double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain [J].

Henderson, DC ;

Copeland, PM ;

Daley, TB ;

Borba, CP ;

Cather, C ;

Nguyen, DD ;

Louie, PM ;

Evins, AE ;

Freudenreich, O ;

Hayden, D ;

Goff, DC .

AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (05) :954-962

[7]

Newcomer JW, 2007, J CLIN PSYCHIAT, V68, P20

[8]

Ryan DH, 2004, PHARMACOTHERAPY OF OBESITY: OPTIONS AND ALTERNATIVES, P245, DOI 10.1201/9780203508756.ch12

← 1 →